Longcor Jarrod's Insider Trades & SAST Disclosures
Longcor Jarrod's most recent trade in Cellectar Biosciences Inc was a trade of 500,000 Stock option (right to buy) done . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Longcor Jarrod.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 500,000 | 500,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.28 per share. | 10 Jan 2025 | 30,000 | 83,141 (0%) | 0% | 0.3 | 8,400 | Common Stock |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 500,000 | 500,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Longcor Jarrod | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 144,000 | 144,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 42,927 | 53,141 (0%) | 0% | 0 | Common Stock | |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 144,000 | 144,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 475,000 | 475,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 450,000 | 450,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 28 Dec 2020 | 29,630 | 102,148 (1%) | 0% | 1.4 | 40,001 | Common Stock |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 05 Jun 2020 | 65,218 | 72,518 (0%) | 0% | 1.1 | 74,675 | Common Stock |
| Cellectar Biosciences Inc | Jarrod Longcor | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Jun 2020 | 32,609 | 32,609 | - | - | Series H Warrants |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges